During, and after, menopause >50% of women experience symptoms of vulvovaginal atrophy, which includes vaginal dryness, itching/burning sensation and pain during sexual intercourse. Intrarosa is a medicine used to treat postmenopausal women with moderate to severe symptoms of vulvar and vaginal atrophy. In these women, the wall of the vagina and surrounding tissues become thinner and can cause symptoms such as dryness, irritation and soreness around the genital area, and painful sexual intercourse. 

Intrarosa contains the active substance prasterone (also known as dehydroepiandrosterone, DHEA) which is biochemically and biologically identical to endogenous human DHEA. 

DHEA is an inactive precursor steroid, which will be converted to estrogens and androgens (eg testosterone), once taken up into vaginal cells. Intrarosa is therefore different than local estrogenic treatments (eg Vagifem®) through the dual action of estrogens and androgens. 

Links to product sites:

Intrarosa (prasterone), Vaginal pessary, Rx, EF

ATC code

Indication area
Intrarosa is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.

Avia Pharma AB (Product website)

Last SPC review

Intrarosa for the treatment of postmenopausal symptoms should only be started if the symptoms have a negative impact on quality of life. Treatment with Intrarosa should only be continued as long as the benefits outweigh the risks.

Please carefully study the information contained in the leaflet or, as applicable, on the outer packaging.

Please refer to for more information regarding price, more specific warnings etc.

Please note that the information you will find in this section is for healthcare professionals

Please confirm that you are a healthcare professional